Company Overview - Wuzhou Medical closed at 42.22 yuan, up 1.96%, with a rolling PE ratio of 99.97 times and a total market value of 2.871 billion yuan [1] - The company ranks 105th in the medical device industry, which has an average PE ratio of 56.95 times and a median of 40.49 times [1] Shareholder Information - As of July 31, 2025, Wuzhou Medical had 7,255 shareholders, an increase of 848 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Anhui Hongyu Wuzhou Medical Device Co., Ltd. specializes in the R&D, manufacturing, and sales of disposable sterile infusion medical devices, along with other diagnostic and nursing supplies [1] - The main products include syringes, infusion and blood transfusion devices, medical puncture needles, and other diagnostic and clinical care products [1] - The company holds 46 medical device product registration and filing certificates as of the reporting period [1] Financial Performance - In the latest semi-annual report for 2025, the company achieved operating revenue of 217 million yuan, a decrease of 2.26% year-on-year, and a net profit of 10.5151 million yuan, down 51.69% year-on-year, with a gross sales margin of 14.33% [1]

五洲医疗收盘上涨3.41%，滚动市盈率45.71倍，总 市值18.54亿元 3月26日，五洲医疗今日收盘27.26元，上涨3.41%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到45.71倍，总市值18.54亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.14倍，行业中值31.99倍，五洲医疗排 名第87位。 股东方面，截至2025年3月10日，五洲医疗股东户数6536户，较上次增加139户，户均持股市值35.28万 元，户均持股数量2.76万股。 安徽宏宇五洲医疗器械股份有限公司的主营业务为一次性使用无菌输注类医疗器械的研发、生产和销 售，以及其他诊断护理等相关医疗用品的集成供应。公司主要产品有注射器、输液输血器、医用穿刺 针、其他诊断和临床护理产品四个系列。公司已经获得国家高新技术企业、安徽省企业技术中心、安徽 省省级工业设计中心等认定，并建立了完善的质量管理体系，且已获得了德国南德意志集团 (TüVSüD)ISO13485:2016医疗器械质量管理体系认证、欧盟CE产品认证、美国FDA企业注册和产品列 名。 最新一期业绩显示，2024年三季报，公司实现营业收入3.43 ...